StevenALimentaniMD

PubMed

• 11 citations
  Adjuvant trastuzumab emtansine in HER2-positive breast cancer patients with HER2-negative residual invasive disease in KATHERINE.
  Sibylle Loibl, Chiun-Sheng Huang, Max S Mano, Eleftherios P Mamounas, Charles E Geyer Jr, Michael Untch, Jean-Christophe Thery, Ingo Schwaner, Steven Limentani, Niklas...> ;NPJ Breast Cancer. 2022 Sep 19
• Re: Using the 21‐gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial. Journal of Surgical Oncology 2017;115(8):91...
  Harry D. Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani, Richard L. White, James Granfortuna, Judith O. Hopkins, Dwight Oldham, Angel Rodriguez, Amy P. Sing> ;Journal of Surgical Oncology. 2017 Jul 28
• 67 citations
  Using the 21-gene assay from core needle biopsies to choose neoadjuvant therapy for breast cancer: A multicenter trial.
  Harry D. Bear, Wen Wan, André Robidoux, Peter Rubin, Steven Limentani, Richard L. White, James Granfortuna, Judith O. Hopkins, Dwight Oldham, Angel Rodriguez, Amy P. Sing> ;Journal of Surgical Oncology. 2017 Jun 1
• Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a pha...
  Martin M, Fumoleau P, Dewar JA, Albanell J, Limentani SA, Campone M, Chang JC, Patre M, Strasak A, de Haas SL, Xu J, Garcia-Saenz JA> ;Ann. Oncol.. 2016-07-01
• 25 citations
  A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
  Steven A. Limentani, Mario Campone, Thierry Dorval, Giuseppe Curigliano, Richard De Boer, Charles L. Vogel, Shane White, Thomas Bachelot, Jean-Luc Canon, Mary L. Disis...> ;Breast Cancer Research and Treatment. 2016 Mar 18
• 17 citations
  Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in wome...
  Jame Abraham, André Robidoux, Antoinette R. Tan, Steven A. Limentani, Keren Sturtz, Ibrahim A. Shalaby, Hope Alcorn, Marc Buyse, Norman Wolmark, Samuel A. Jacobs> ;Breast Cancer Research and Treatment. 2015 Jul 1
• 38 citations
  Trebananib (AMG 386) plus weekly paclitaxel with or without bevacizumab as first-line therapy for HER2-negative locally recurrent or metastatic breast cancer: A phase ...
  Véronique Diéras, Hans Wildiers, Jacek Jassem, Luc Dirix, Jean-Paul Guastalla, Petri Bono, Sara A. Hurvitz, Anthony Gonçalves, Gilles Romieu, Steven A. Limentani, Guy ...> ;Breast. 2015 Jun 1
• 53 citations
  Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2‑positive breast cancer: an NSABP Foundation Resear...
  Rachel C. Jankowitz, Jame Abraham, Antoinette R. Tan, Steven Limentani, Marni B. Tierno, Laura M Adamson, Marc Buyse, Norman Wolmark, Samuel A. Jacobs> ;Cancer Chemotherapy and Pharmacology. 2013 Sep 29
• A phase I dose-escalation and pharmacokinetic (PK) evaluation of an oral AKT inhibitor, LY2503029 (LY).
  Limentani SA, Burris H, Anderson AP, Brail LH, Satonin D, Gueorguieva I, Jones S, Infante JR, Bendell JC> ;J. Clin. Oncol.. 2011-05-20
• A randomized, placebo-controlled phase II study of AMG 386 plus bevacizumab (Bev) and paclitaxel (P) or AMG 386 plus P as first-line therapy in patients (pts) with HER...
  Dieras V, Jassem J, Dirix LY, Guastalla JP, Bono P, Hurvitz SA, Gonçalves A, Romieu G, Limentani SA, Jerusalem GHM, Lakshmaiah K, Roche HH, Sánchez-Rovira P, Pienkowsk...> ;J. Clin. Oncol.. 2011-05-20
• 511 citations
  Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior ...
  Howard A. Burris, Hope S. Rugo, Svetislava J. Vukelja, Charles L. Vogel, Rachel A. Borson, Steven A. Limentani, Elizabeth Tan-Chiu, Ian E. Krop, Richard Alan Michaelso...> ;Journal of Clinical Oncology. 2011 Feb 1
• 134 citations
  Efficacy and Safety of Axitinib in Patients With Advanced Non–Small-Cell Lung Cancer: Results From a Phase II Study
  Joan H. Schiller, Timothy S. Larson, S.-H. Ignatius Ou, Steven A. Limentani, Alan B. Sandler, Everett E. Vokes, Sinil Kim, K. F. Liau, Paul Bycott, Anthony J. Olszansk...> ;Journal of Clinical Oncology. 2009 Aug 10
• Safety and efficacy of neratinib (HKI-272) in combination with vinorelbine in patients with solid tumors.
  Limentani SA, Awada A, Dirix L, Beck J, Dieras V, Binlich F, Germa C, Agrapart V, Powell C, Hershman D> ;J. Clin. Oncol.. 2009-05-20
• A phase II study of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate (ADC), in patients (pts) with HER2+ metastatic breast cancer (MBC): Final results.
  Vogel CL, Burris HA, Limentani S, Borson R, O'Shaughnessy J, Vukelja S, Agresta S, Klencke B, Birkner M, Rugo H> ;J. Clin. Oncol.. 2009-05-20
• 16 citations
  Assessing quality of life following neoadjuvant therapy for early stage non-small cell lung cancer (NSCLC): results from a prospective analysis using the Lung Cancer S...
  Richard J. Gralla, Martin J. Edelman, Frank C. Detterbeck, Thierry Jahan, David M. Loesch, Steven A. Limentani, Ramaswamy Govindan, Guangbin Peng, Matthew J. Monberg, ...> ;Supportive Care in Cancer. 2009 Mar 1
• 73 citations
  Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma
  Sundar Jagannath, Bart Barlogie, James R. Berenson, David S. Siegel, David Irwin, Paul G. Richardson, Ruben Niesvizky, Raymond Alexanian, Steven A. Limentani, Melissa ...> ;British Journal of Haematology. 2008 Nov 1
• 34 citations
  Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and pacli...
  Thomas E. Stinchcombe, Carrie B. Lee, Dominic T. Moore, M. Patricia Rivera, Jan Halle, Steven Limentani, Julian G. Rosenman, Mark A. Socinski> ;Journal of Thoracic Oncology. 2008 Nov 1
• A phase I dose escalation and pharmacokinetic (PK) study of intravenous (iv) aflibercept (VEGF Trap) plus FOLFOX4 in patients (pts) with advanced solid tumors: Prelimi...
  Limentani S, Just R, Purdham A, Mulay M, Bair A, Tamby JF, Chap LI, Rosen LS> ;J. Clin. Oncol.. 2008-05-20
• 18 citations
  Neoadjuvant chemotherapy with gemcitabine-containing regimens in patients with early-stage non-small cell lung cancer
  Frank C. Detterbeck, Mark A. Socinski, Richard J. Gralla, Martin J. Edelman, Thierry Jahan, David M. Loesch, Steven A. Limentani, Ramaswamy Govindan, M.B. Zaman, Z. Ye...> ;Journal of Thoracic Oncology. 2008 Jan 1
• 63 citations
  Phase II study of neoadjuvant docetaxel, vinorelbine, and trastuzumab followed by surgery and adjuvant doxorubicin plus cyclophosphamide in women with human epidermal ...
  Steven A. Limentani, Adam M. Brufsky, John K. Erban, M. Jahanzeb, Deborah Lewis> ;Journal of Clinical Oncology. 2007 Apr 1
• 469 citations
  Frequency, Characteristics, and Reversibility of Peripheral Neuropathy During Treatment of Advanced Multiple Myeloma With Bortezomib
  Paul G. Richardson, Hannah R. Briemberg, Sundar Jagannath, Patrick Y. Wen, Bart Barlogie, James R. Berenson, Seema Singhal, David S. Siegel, David Irwin, Michael W. Sc...> ;Journal of Clinical Oncology. 2006 Jul 1
• A phase 1, dose-escalation trial of STA-5312, a microtubule inhibitor with a novel binding site, in advanced or metastatic solid malignancies.
  Desai A, Ratain MJ, Moshier K, Tipton M, Dooley W, Hocknell K, Dahl T, Sherman M, Limentani S> ;J. Clin. Oncol.. 2006-06-20
• Safety and pharmacokinetics of intravenous VEGF Trap plus FOLFOX4 in a combination phase I clinical trial of patients with advanced solid tumors.
  Mulay M, Limentani SA, Carroll M, Furfine ES, Cohen DP, Rosen LS> ;J. Clin. Oncol.. 2006-06-20
• Evaluation of a recombinant HER2 vaccine: Induction of specific antibodies, T-cells and preliminary activity in metastatic breast cancer patients.
  Limentani SA, Campone M, Dorval T, Tan-Chiu E, Curigliano G, De Boer R, Canon J, Bachelot T, Louahed J, Brichard VG> ;J. Clin. Oncol.. 2006-06-20
• 7 citations
  Phase II Study of Neoadjuvant Docetaxel/Vinorelbine Followed by Surgery and Adjuvant Doxorubicin/Cyclophosphamide in Women with Stage II/III Breast Cancer
  Steven A. Limentani, Affair M. Brufsky, John K. Erban, M. Jahanzeb, Deborah Lewis> ;Clinical Breast Cancer. 2006 Feb 1
• Join now to see all